Breast Cancer (ASCO) Basic Listing

Updates in Breast Cancer

From the ASCO Annual Meeting

Kevin Kalinsky, MD, Winship Cancer Institute

Videos

Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

06/13/2024

Kevin Kalinsky, MD

Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...

Kevin Kalinsky, MD, shares...

06/13/2024

Oncology

Rebecca Shatsky, MD, University of California, San Diego

Videos

Datopotamab Deruxtecan Plus Durvalumab for Certain Patients With Advanced Breast Cancer

06/07/2024

Rebecca Shatsky, MD

Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.

Rebecca Shatsky, MD, shares...

06/07/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan Remains Superior to Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer

06/07/2024

Allison Casey

According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.

According to updated survival...

06/07/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan Improves Progression-Free Survival Among Patients With HER2-Low Metastatic Breast Cancer

06/06/2024

Allison Casey

According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.

According to first results from...

06/06/2024

Oncology

Conference Coverage

Pembrolizumab Plus Sacituzumab Govitecan for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/06/2024

Allison Casey

According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.

According to results from a...

06/06/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan for Patients With Previous Treated HR-Positive, HER2-Negative Breast Cancer

06/03/2024

Jane Meisel, MD

Jane Meisel, MD, discussed results from the I-SPY 2.2 trial which investigated the clinical activity of datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer.

Jane Meisel, MD, discussed...

06/03/2024

Oncology

Conference Coverage

Palbociclib Plus Exemestane and Ovarian Function Suppression for HR-Positive, HER2-Negative Breast Cancer

06/02/2024

Allison Casey

According to updated survival data from the phase 2 Young-PEARL study, palbociclib plus exemestane with ovarian function suppression prolonged progression-free survival but not overall survival among patients with HR-positive, HER2-negative...

According to updated survival...

06/02/2024

Oncology

Conference Coverage

Inavolisib Plus Palbociclib and Fulvestrant Showed Clinical Benefit Post-Progression Among Patients With PIK3A-Mutated, HR-Positive, HER2-Negative Breast Cancer

05/31/2024

Stephanie Holland

According to updated results from the INAVO120 trial, inavolisib plus palbociclib and fulvestrant sustained clinical benefit beyond disease progression among patients with PIK3A-mutated, HR-positive, HER2-negative, locally advanced or...

According to updated results...

05/31/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan With or Without Pertuzumab Shows Promise For Previously Untreated Patients With HER2-Positive Metastatic Breast Cancer

05/28/2024

Allison Casey

According to a phase 1b/2 trial, trastuzumab deruxtecan with or without pertuzumab showed promising efficacy among previously untreated patients with HER2-positive metastatic breast cancer, with safety profiles consistent with the known...

According to a phase 1b/2 trial,...

05/28/2024

Oncology

Conference Coverage

Sacituzumab Tirumotecan Improves Survival Outcomes Among Patients With Advanced Triple-Negative Breast Cancer

05/28/2024

Allison Casey

According to phase 3 data to be presented at the 2024 ASCO Annual Meeting, sacituzumab tirumotecan improved progression-free survival and overall survival compared to chemotherapy with manageable safety for heavily pre-treated patients with...

According to phase 3 data to be...

05/28/2024

Oncology

Recent News

Conference Coverage

Inavolisib Plus Palbociclib and Fulvestrant Showed Clinical Benefit Post-Progression Among Patients With PIK3A-Mutated, HR-Positive, HER2-Negative Breast Cancer

05/31/2024

Stephanie Holland

According to updated results...

05/31/2024

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology